Discussion
The U.S. Food and Drug Administration (FDA) is slated to decide by early next year whether or not to approve a one-time gene-editing therapy to potentially control swelling in hereditary angioedema (HAE). The regulatory agency accepted an application from Intellia Therapeutics seeking approval of its infusion therapy…